Author

Scott Pearsall

Observed names: S. Pearsall, S.R. Pearsall

Institution: Acceleron Pharma (United States)

Observed institution: Acceleron Pharma (United States)

OpenAlex ID: A5044249790

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

2010 · Andrew D Chantry, Debby Heath, et al. · Journal of Bone and Mineral Research · 147

A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health

2010 · Alan Koncarevic, Milton Cornwall-Brady, et al. · Endocrinology · 71

Differential Muscle Hypertrophy Is Associated with Satellite Cell Numbers and Akt Pathway Activation Following Activin Type IIB Receptor Inhibition in Mtm1 p.R69C Mice

2014 · Michael W. Lawlor, Marissa G. Viola, et al. · American Journal Of Pathology · 37

Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.

2014 · Antonio Jimeno, Marshall R. Posner, et al. · Journal of Clinical Oncology · 5

Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.

2010 · N. G. Borgstein, S. Sharma, et al. · Journal of Clinical Oncology · 3

Abstract 1692: Dalantercept, an ALK1 inhibitor of angiogenesis, in combination with cisplatin inhibits tumor growth in a xenograft model of squamous cell carcinoma of the head and neck

2014 · Marat Alimzhanov, Michael Lee, et al. · Cancer Research · 2

BMP9 as a potential biomarker for dalantercept efficacy against ALK1-mediated angiogensis in head and neck cancer.

2012 · Scott Pearsall, Nicolas Solban, et al. · Journal of Clinical Oncology · 2

An investigative pharmacology study of a GDF‐8 (myostatin) inhibitor, ACE‐031, in the Common Marmoset (Callithrix Jacchus)

2008 · Scott Pearsall, Lynn Wachtman, et al. · The FASEB Journal · 2

Abstract 17217: ActRIIA-Fc Rebalances Activin/GDF and BMP9 Signaling to Attenuate Experimental Pulmonary Hypertension

2018 · Lai-Ming Yung, Peiran Yang, et al. · Circulation · 1

Abstract 17285: A Selective Transforming Growth Factor-β and Growth Differentiation Factor-15 Ligand Trap Attenuates Pulmonary Hypertension

2014 · Lai-Ming Yung, Samuel D Paskin-Flerlage, et al. · Circulation · 1

Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

2013 · Antonio Jimeno, Lori J. Wirth, et al. · Journal of Clinical Oncology · 1

Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.

2013 · Rupal Satish Bhatt, Xiaoen Wang, et al. · Journal of Clinical Oncology · 1

Abstract 19307: A Selective Tgfβ Ligand Trap Attenuates Pulmonary Hypertension

2016 · Lai‐Ming Yung, Ivana Nikolić, et al. · Circulation

O-015 Inhibition of Smad2/3 signaling by ACE-536 corrects anemia and ineffective erythropoiesis in myelodysplastic syndromes

2013 · R. Suragani, S. Cawley, et al. · Leukemia Research

Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

2012 · Andrew D Chantry, Debby Heath, et al. · Journal of Bone and Mineral Research

Erratum: Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

2012 · Andrew D Chantry, Debby Heath, et al. · Journal of Bone and Mineral Research

Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma

2009 · A. Chantry, L. Coulton, et al. · Bone

Works count: 17

Citation count: 273

H-index: 4

I10-index: 3